Schedule 13D - Activist Investments
NASDAQ
Joseph S. Freedman increased his beneficial ownership in Eupraxia Pharmaceuticals Inc. to 9.0% through recent share purchases and warrant exercises.
Capital raise
NASDAQ
SCHEDULE: Freedman Boosts Eupraxia Stake to 10.2%
Joseph S. Freedman increased his beneficial ownership in Eupraxia Pharmaceuticals Inc. to 10.2% after purchasing 543,130 common shares in a recent public offering.
Capital raise
Schedule 13G - Passive Investments
See all →NASDAQ
Several Manchester entities and individuals have updated their beneficial ownership filings for EUPRAXIA PHARMACEUTICALS INC. common shares, with aggregate holdings now reported.
NASDAQ
Manchester Management and associated parties have filed a Schedule 13G reporting a combined 7.7% beneficial ownership stake in Eupraxia Pharmaceuticals Inc.
NASDAQ
Manchester Management entities and individuals James E. Besser and Morgan C. Frank have disclosed a significant beneficial ownership stake in Eupraxia Pharmaceuticals Inc., with Morgan C. Frank holding the largest individual percentage at 9.2%.
NASDAQ
Robert Disbrow has filed an amended Schedule 13G, reporting a beneficial ownership of 7.0% in Eupraxia Pharmaceuticals Inc. as of September 30, 2025.
NASDAQ
Beutel, Goodman & Co Ltd., a Canadian investment adviser, has disclosed an 8.02% beneficial ownership stake in EUPRAXIA PHARMACEUTICALS INC. common shares.
NASDAQ
A group of Manchester entities and individuals have disclosed beneficial ownership exceeding 10% of Eupraxia Pharmaceuticals Inc.'s Common Shares.